RecruitingNCT05027828

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Enrollment

100 participants

Start Date

Sep 1, 2021

Study Type

OBSERVATIONAL

Conditions

Circulating Tumor DNA High Grade Serous Ovarian Cancer

Summary

This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a blood test that detects tiny fragments of tumor DNA (called ctDNA) to track how well treatment is working in patients with ovarian cancer. The goal is to find out if this simple blood test can be used as an early signal of treatment success or failure — before traditional imaging would show changes. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer at Stage II–IV - You are scheduled to have surgery **You may NOT be eligible if...** - Your ovarian cancer is a non-epithelial type (e.g., germ cell or stromal tumor) - Surgery is not possible based on your doctor's evaluation - You have had another cancer in the past 5 years - You have severe heart disease, uncontrolled infection, or serious uncontrolled other illnesses - You have a severe mental illness Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05027828

Related Trials

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

NCT0500540344 locations

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT0557936666 locations